8I8 Stock Chart & Stats
€0.43
€0.01(2.90%)
At close: 4:00 PM EDT
€0.43
€0.01(2.90%)
Day’s Range― - ―
52-Week Range€0.28 - €0.71
Previous CloseN/A
Volume0.00
Average Volume (3M)34.00
Market Cap
€277.24M
Enterprise Value€199.41
Total Cash (Recent Filing)€2.13B
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)11.7
Beta-0.10
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.40
Shares Outstanding581,326,300
10 Day Avg. Volume103
30 Day Avg. Volume34
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)6.10
Price to Sales (P/S)2.63
P/FCF Ratio14.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.4
Revenue Forecast (FY)€8.61B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue AccelerationRevenue accelerated to +16.1% in 2025 after solid growth in prior years, signaling durable demand and scale in diagnostics. Sustained top-line momentum supports recurring testing volumes, improves unit economics via operating leverage, and funds capex or network expansion over months.
High Operating ProfitabilityHigh operating margins (EBIT ~29.6%, EBITDA ~36.8%, net ~16.1%) reflect efficient lab operations and pricing power in diagnostics. Durable profitability underpins consistent cash generation, funds reinvestment into technology and capacity, and provides a buffer against moderate cost inflation.
Improving Leverage And Strong ROEDebt-to-equity improvement paired with a very strong ROE (~37.3%) indicates effective capital deployment and strengthening balance sheet resilience. Manageable leverage increases capacity for strategic M&A or targeted capex while maintaining shareholder return potential over the medium term.
Bears Say
Rising Absolute DebtAbsolute debt increases, despite improved ratios, raise interest and refinancing exposure over time. If margins or revenue growth soften, higher nominal debt can constrain cash available for operations, capex and strategic moves, reducing financial flexibility over the coming months.
Inconsistent Cash ConversionVolatile FCF conversion—73% of net income in 2025 after declines and a negative FCF year—signals working-capital or investment timing risks. Inconsistent cash generation can impede reliable funding of debt reduction, capex or dividends and complicate medium-term planning.
Margin Erosion Vs Earlier PeaksA dip in net margin versus 2024 and lower margins than 2020–2021 imply emerging cost pressures or unfavorable service mix. Continued margin compression would lower free cash flow and returns, challenging reinvestment and weakening resilience to cyclical or structural industry cost increases.
Integrated Diagnostics Holdings News
8I8 FAQ
What was Integrated Diagnostics Holdings PLC’s price range in the past 12 months?
Integrated Diagnostics Holdings PLC lowest stock price was €0.28 and its highest was €0.71 in the past 12 months.
What is Integrated Diagnostics Holdings PLC’s market cap?
Integrated Diagnostics Holdings PLC’s market cap is €277.24M.
When is Integrated Diagnostics Holdings PLC’s upcoming earnings report date?
Integrated Diagnostics Holdings PLC’s upcoming earnings report date is Aug 27, 2026 which is in 19 days.
How were Integrated Diagnostics Holdings PLC’s earnings last quarter?
Currently, no data Available
Is Integrated Diagnostics Holdings PLC overvalued?
According to Wall Street analysts Integrated Diagnostics Holdings PLC’s price is currently Overvalued.
Does Integrated Diagnostics Holdings PLC pay dividends?
Integrated Diagnostics Holdings PLC does not currently pay dividends.
What is Integrated Diagnostics Holdings PLC’s EPS estimate?
Integrated Diagnostics Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrated Diagnostics Holdings PLC have?
Integrated Diagnostics Holdings PLC has 581,326,300 shares outstanding.
What happened to Integrated Diagnostics Holdings PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Integrated Diagnostics Holdings PLC?
Currently, no hedge funds are holding shares in DE:8I8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integrated Diagnostics Holdings Stock Smart Score
Company Description
Integrated Diagnostics Holdings PLC
Integrated Diagnostics Holdings plc (IDHC.L) functions as a leading consumer healthcare enterprise, offering a wide array of medical diagnostic services directly to its clientele. The company's comprehensive service catalog features around 2,000 distinct diagnostic examinations, spanning specialized fields such as immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. Geographically, IDHC has established operations across Egypt, Jordan, Sudan, and Nigeria. As of December 30, 2021, its infrastructure included an extensive network of 452 laboratory branches. The organization was founded in 1979 and maintains its corporate headquarters in Saint Helier, Jersey.
Technical Analysis
Bioventix
―
EKF Diagnostics Holdings
―
Genedrive
―
Omega Diagnostics
―
Abingdon Health PLC
―